SARS 患者血清对 SARS-CoV-2 缺乏交叉中和作用。
Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2.
机构信息
Duke-NUS Medical School, Singapore, Singapore.
National Center for Infectious Diseases, Singapore, Singapore.
出版信息
Emerg Microbes Infect. 2020 Dec;9(1):900-902. doi: 10.1080/22221751.2020.1761267.
Abstract
Despite initial findings indicating that SARS-CoV and SARS-CoV-2 are genetically related belonging to the same virus species and that the two viruses used the same entry receptor, angiotensin-converting enzyme 2 (ACE2), our data demonstrated that there is no detectable cross-neutralization by SARS patient sera against SARS-CoV-2. We also found that there are significant levels of neutralizing antibodies in recovered SARS patients 9-17 years after initial infection. These findings will be of significant use in guiding the development of serologic tests, formulating convalescent plasma therapy strategies, and assessing the longevity of protective immunity for SARS-related coronaviruses in general as well as vaccine efficacy.
摘要
尽管最初的研究结果表明，SARS-CoV 和 SARS-CoV-2 在基因上具有相关性，属于同一病毒种，并且这两种病毒使用相同的进入受体血管紧张素转换酶 2（ACE2），但我们的数据表明，SARS 患者的血清对 SARS-CoV-2 没有可检测到的交叉中和作用。我们还发现，在初次感染后 9-17 年，康复的 SARS 患者体内存在大量中和抗体。这些发现将有助于指导血清学检测的开发、制定恢复期血浆治疗策略，并评估 SARS 相关冠状病毒的保护性免疫的持久性以及疫苗的有效性。
相似文献
1
Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2.SARS 患者血清对 SARS-CoV-2 缺乏交叉中和作用。
Emerg Microbes Infect. 2020 Dec;9(1):900-902. doi: 10.1080/22221751.2020.1761267.
2
Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization.针对严重急性呼吸综合征冠状病毒 2 型的抗体及其在治疗性被动免疫中的潜在作用。
Elife. 2020 Jun 23;9:e57877. doi: 10.7554/eLife.57877.
3
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.在人源化小鼠和恢复期患者中的研究产生了一种 SARS-CoV-2 抗体鸡尾酒。
Science. 2020 Aug 21;369(6506):1010-1014. doi: 10.1126/science.abd0827. Epub 2020 Jun 15.
4
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.SARS-CoV-2 刺突糖蛋白的特征及其对病毒进入的影响，以及与 SARS-CoV 的免疫交叉反应性。
Nat Commun. 2020 Mar 27;11(1):1620. doi: 10.1038/s41467-020-15562-9.
5
Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population.SARS-CoV-2 感染后恢复期人群 B 细胞线性表位的功能图谱。
Emerg Microbes Infect. 2020 Dec;9(1):1988-1996. doi: 10.1080/22221751.2020.1815591.
6
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.人类单克隆 SARS-CoV 抗体对 SARS-CoV-2 的交叉中和作用。
Nature. 2020 Jul;583(7815):290-295. doi: 10.1038/s41586-020-2349-y. Epub 2020 May 18.
7
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies.人类抗体与 SARS-CoV-2 刺突结合的结构揭示了常见表位和抗体的反复出现特征。
Cell. 2020 Aug 20;182(4):828-842.e16. doi: 10.1016/j.cell.2020.06.025. Epub 2020 Jun 24.
8
Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2.针对 SARS-CoV-1 刺突蛋白 S2 亚基的单克隆抗体与新出现的 SARS-CoV-2 发生交叉反应。
Euro Surveill. 2020 Jul;25(28). doi: 10.2807/1560-7917.ES.2020.25.28.2000291.
9
Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2.关于新型冠状病毒 SARS-CoV-2 的结构和修复方面的研究进展。
Curr Top Med Chem. 2020;20(26):2362-2378. doi: 10.2174/1568026620666200922112300.
10
The convalescent sera option for containing COVID-19.使用康复期血清来控制新型冠状病毒肺炎。
J Clin Invest. 2020 Apr 1;130(4):1545-1548. doi: 10.1172/JCI138003.
引用本文的文献
1
AI-driven multi-omics modeling of myalgic encephalomyelitis/chronic fatigue syndrome.肌痛性脑脊髓炎/慢性疲劳综合征的人工智能驱动多组学建模
Nat Med. 2025 Jul 25. doi: 10.1038/s41591-025-03788-3.
2
Immune responses to SARS-CoV-2 infection in Humans and ACE2 humanized mice.人类和ACE2人源化小鼠对SARS-CoV-2感染的免疫反应。
Fundam Res. 2021 Mar;1(2):124-130. doi: 10.1016/j.fmre.2021.03.001. Epub 2021 Mar 3.
3
The Batalogue: an overview of betacoronaviruses with future pandemic potential.《目录：具有未来大流行潜力的β冠状病毒概述》
FEMS Microbiol Rev. 2025 Jan 14;49. doi: 10.1093/femsre/fuaf023.
4
Broad cross neutralizing antibodies against sarbecoviruses generated by SARS-CoV-2 infection and vaccination in humans.人类感染新冠病毒和接种疫苗后产生的针对沙贝病毒属病毒的广泛交叉中和抗体。
NPJ Vaccines. 2024 Oct 22;9(1):195. doi: 10.1038/s41541-024-00997-8.
5
BioMapAI: Artificial Intelligence Multi-Omics Modeling of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome.生物图谱人工智能：肌痛性脑脊髓炎/慢性疲劳综合征的人工智能多组学建模
bioRxiv. 2025 Feb 13:2024.06.24.600378. doi: 10.1101/2024.06.24.600378.
6
Effect of seasonal coronavirus immune imprinting on the immunogenicity of inactivated COVID-19 vaccination.季节性冠状病毒免疫印迹对灭活 COVID-19 疫苗免疫原性的影响。
Front Immunol. 2023 Aug 16;14:1195533. doi: 10.3389/fimmu.2023.1195533. eCollection 2023.
7
Research progress in methods for detecting neutralizing antibodies against SARS-CoV-2.新型冠状病毒中和抗体检测方法的研究进展。
Anal Biochem. 2023 Jul 15;673:115199. doi: 10.1016/j.ab.2023.115199. Epub 2023 May 29.
8
SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines.严重急性呼吸综合征冠状病毒2：免疫、当前疫苗面临的挑战以及黏膜疫苗的新视角
Vaccines (Basel). 2023 Apr 15;11(4):849. doi: 10.3390/vaccines11040849.
9
Validation of a SARS-CoV-2 Surrogate Virus Neutralization Test in Recovered and Vaccinated Healthcare Workers.验证 SARS-CoV-2 替代病毒中和试验在康复和接种疫苗的医护人员中的效果。
Viruses. 2023 Feb 2;15(2):426. doi: 10.3390/v15020426.
10
Persistent humoral and CD4 T cell immunity after mild SARS-COV-2 infection-The CoNAN long-term study.轻度 SARS-CoV-2 感染后持久的体液和 CD4 T 细胞免疫：CoNAN 长期研究。
Front Immunol. 2023 Jan 13;13:1095129. doi: 10.3389/fimmu.2022.1095129. eCollection 2022.
本文引用的文献
1
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）进入细胞依赖于 ACE2 和 TMPRSS2，可被一种临床验证的蛋白酶抑制剂所阻断。
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
2
Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.新加坡 2019 年新型冠状病毒肺炎患者的流行病学特征和临床病程
JAMA. 2020 Apr 21;323(15):1488-1494. doi: 10.1001/jama.2020.3204.
3
A pneumonia outbreak associated with a new coronavirus of probable bat origin.一种新型冠状病毒引发的肺炎疫情，该病毒可能来源于蝙蝠。
Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.
4
Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection.抗刺突 IgG 通过在急性 SARS-CoV 感染期间使巨噬细胞反应发生偏斜，导致严重的急性肺损伤。
JCI Insight. 2019 Feb 21;4(4). doi: 10.1172/jci.insight.123158.
5
Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor.一种使用 ACE2 受体的蝙蝠 SARS 样冠状病毒的分离与鉴定
Nature. 2013 Nov 28;503(7477):535-8. doi: 10.1038/nature12711. Epub 2013 Oct 30.
6
Second generation of pseudotype-based serum neutralization assay for Nipah virus antibodies: sensitive and high-throughput analysis utilizing secreted alkaline phosphatase.第二代基于假型病毒的尼帕病毒抗体血清中和检测法：利用分泌型碱性磷酸酶进行灵敏、高通量分析。
J Virol Methods. 2012 Jan;179(1):226-32. doi: 10.1016/j.jviromet.2011.11.003. Epub 2011 Nov 18.
7
Determination and application of immunodominant regions of SARS coronavirus spike and nucleocapsid proteins recognized by sera from different animal species.不同动物物种血清所识别的严重急性呼吸综合征冠状病毒刺突蛋白和核衣壳蛋白免疫显性区域的确定及应用
J Immunol Methods. 2008 Feb 29;331(1-2):1-12. doi: 10.1016/j.jim.2007.11.009. Epub 2007 Dec 17.
8
Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts.新加坡的严重急性呼吸综合征（SARS）：首例患者及最初接触者的临床特征
Emerg Infect Dis. 2003 Jun;9(6):713-7. doi: 10.3201/eid0906.030264.
Zotero 插件